You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of a novel non-invasive device for measuring the mechanical properties of cortical bone

    SBC: OSTEODX INC            Topic: NIA

    Abstract AEIOU ScientificLLCAEIOUaims to develop and commercialize Ohio Universityandapos sOHIOandapos spatent pending Cortical Bone Mechanics TechnologyCBMTas a non invasive medical device for improving the diagnosis and monitoring of osteoporosis and other bone diseasesOsteoporosis and low bone mass affectmillion Americans andmillion people worldwideIn womenthe resulting fragility fractures caus ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. PLGA encapsulated polyphenols to ameliorate IBD.

    SBC: THERAPYX, INC.            Topic: R

    Abstract Green tea has received increased attention recentlydue to several epidemiological and clinical studies showing a positive relationship between consumption and disease preventionBenefits include reduced risk of cardiovascular diseasese gmyocardial infarctionhypertensionatherosclerosisneurodegenerative diseasese gParkinson s and Alzheimer s diseaseand certain cancerse ggastricbreast and cer ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Left atrial appendage closure device with catheter-based delivery for patients with non-valvular atrial fibrillation

    SBC: Cor Habere Corp.            Topic: R

    In the USthere aremillion patients with nonvalvular atrial fibrillationNVAFwhich is expected to increase tomillion byThe treatment of NVAF is estimated to cost $billionincluding $billionfor hospitalizations aloneThe most significant morbidity and mortality associated with NVAF is embolic strokewithof thrombus originating from the left atrial appendageLAAAnticoagulation is the preferred treatment f ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a sutureless LVAD outflow graft anastomotic quick-connect system

    SBC: Myocardial Assist Systems & Technology LLC            Topic: NHLBI

    Heart failureHFis the leading cause of death in the United Statesaffecting nearly six million people at a cost over $billionClinically approved mechanical circulatory supportMCStherapysuch as left ventricular assist devicesLVADscontinue to improve as a viable treatment option for patients with advanced heart failure as evidenced by overimplants over the past five yearsHoweverMCS device therapy can ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Robust Predictor of Colon Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 102

    Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. DIAGNOSTIC TEST FOR METASTATIC KIDNEY CANCER

    SBC: LaGrange Scientific, LLC            Topic: 102

    ABSTRACTThe goal of this Phase I SBIR is to address the absence of measureable and targeted metabolite biomarkers in clear cell renal cell carcinomaccRCCtissues that can predict disease metastasisAn estimatedAmericans were diagnosed with kidney cancer inand approximatelydied as a result of ccRCCprimarily due to metastasis of the cancerUltimatelywe seek to identify those patients with more aggressi ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. AML differentiation therapy

    SBC: CuronBiotech Inc            Topic: 102

    Acute Myeloid LeukemiaAMLis a broad range of disorders that all have the defining feature of leukemic cells with a maturation arrestDespite the fact that AML is the most common form of leukemia in adultsthere have been no changes in standard therapy in overyearsThe traditional chemotherapeutics used exhibit both high toxicity and poor efficacy with a median survival in patients over the age ofof l ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury

    SBC: Allinaire Therapeutics, LLC            Topic: NHLBI

    Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an a MC1R selective companion diagnostic imaging probe

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government